发热伴血小板减少综合征的研究进展
|
摘要
发热伴血小板减少综合征(SFTS)是由发热伴血小板减少综合征病毒感染引起的新发传染病。自2009年发现后,发病率不断升高,发病区域不断扩大,我国已有20余省份报道,此后韩国、日本也相继报道该病病例。SFTS病死率高、发病机制尚未明确,目前无相关疫苗,临床上无特效抗病毒药,对该病的研究尚处于起步阶段。本文对其发病机制、病理改变、临床分期、死亡危险因素、治疗的最新研究进展进行归纳总结。
Severe fever with thrombocytopenia syndrome( SFTS) is a viral infectious disease discovered in 2009,since then the incidence rate has been rising and the prevalence area has been expanding. More than 20 provinces have reported SFTS in China; South Korea and Japan also have reported cases of the disease. The pathogenesis of SFTS is unclear; the lack of effective vaccines or antiviral drugs leads to poor prognosis and high mortality rate. This paper summarized latest progress of the pathogenesis,pathological changes,clinical stage,therapeutic choice and death risk factors of SFTS.
Severe fever with thrombocytopenia syndrome( SFTS) is a viral infectious disease discovered in 2009,since then the incidence rate has been rising and the prevalence area has been expanding. More than 20 provinces have reported SFTS in China; South Korea and Japan also have reported cases of the disease. The pathogenesis of SFTS is unclear; the lack of effective vaccines or antiviral drugs leads to poor prognosis and high mortality rate. This paper summarized latest progress of the pathogenesis,pathological changes,clinical stage,therapeutic choice and death risk factors of SFTS.
引文
[1]李德新.发热伴血小板减少综合征布尼亚病毒概述[J].中华实验和临床病毒学杂志,2011,25(2):81-84. DOI:10. 3760/cma. j. issn. 1003-9279. 2011. 02. 001.Li DX. Fever with thormbocytopenia associated with a Novel Bunyavirus in China[J]. Chinese Journal of Experimental and Clinical Virology,2011,25(2):81-84. DOI:10. 3760/cma. j.issn. 1003-9279. 2011. 02. 001.
[2]唐霜,沈姝,史君明,等.布尼亚病毒目新分类概述[J].生物多样性,2018,26(9):1004-1015. DOI:10. 17520/biods. 2018042.Tang S,Shen S,Shi JM,et al. A review and novel classification of Bunyavirales[J]. Biodiversity Science,2018,26(9):1004-1015. DOI:10. 17520/biods. 2018042.
[3]Kim WY,Choi W,Park SW,et al. Nosocomial transmission of severe fever with thrombocytopenia syndrome in Korea[J]. Clin Infect Dis,2015,60(11):1681-1683. DOI:10. 1093/cid/civ128.
[4]Jianbo ZQWJ. Current status of severe fever with thrombocytopenia syndrome in China[J]. Virol Sin,2017,32(1):51-62. DOI:10.1007/s12250-016-3931-1.
[5]Wang M,Zuo J,Hu K. Identification of severe fever with thrombocytopenia syndrome virus in ticks collected from patients[J]. Int J Infect Dis,2014(29):82-83. DOI:10. 1016/j. ijid. 2014.09. 008.
[6]Yu XJ,Liang MF,Zhang SY,et al. Fever with thrombocytopenia associated with a novel bunyavirus in China[J]. N Engl J Med,2011,364(16):1523-1532. DOI:10. 1056/NEJMoa1010095.
[7]Wu Y,Zhu Y,Gao F,et al. Structures of phlebovirus glycoprotein Gn and identification of a neutralizing antibody epitope[J]. Proc Natl Acad Sci U S A,2017,114(36):E7564-7573. DOI:10. 1073/pnas. 1705176114.
[8]Sun Y,Qi Y,Liu C,et al. Nonmuscle myosin heavy chainⅡA is a critical factor contributing to the efficiency of early infection of severe fever with thrombocytopenia syndrome virus[J]. J Virol,2014,88(1):237-248. DOI:10. 1128/JVI. 02141-13.
[9]Plegge T,Hofmann-Winkler H,Spiegel M,et al. Evidence that processing of the severe fever with thrombocytopenia syndrome virus Gn/Gc polyprotein is critical for viral infectivity and requires an internal Gc signal peptide[J]. Plo S One, 2016,11(11):e166013. DOI:10. 1371/journal. pone. 0166013.
[10]Hofmann H,Li X,Zhang X,et al. Severe fever with thrombocytopenia virus glycoproteins are targeted by neutralizing antibodies and can use DC-SIGN as a receptor for p H-dependent entry into human and animal cell lines[J]. J Virol,2013,87(8):4384-4394. DOI:10. 1128/JVI. 02628-12.
[11]何程程,李阿茜,刘林,等.发热伴血小板减少综合征布尼亚病毒细胞嗜性研究[J].中华实验和临床病毒学杂志,2014,28(1):10-13. DOI:10. 3760/cma. j. issn. 1003-9279. 2014. 01. 004.He CC,Li AQ,Liu L,et al. The susceptibility of culture cells to severe fever with thrombocytopenia syndrome virus[J]. Chinese Journal of Experimental and Clinical Virology,2014,28(1):10-13. DOI:10. 3760/cma. j. issn. 1003-9279. 2014. 01. 004.
[12]张硕,李建东,曲靖,等.发热伴血小板减少综合征病毒细胞表面受体的初步研究[J].微生物与感染,2014,9(2):112-115.Zhang S,Li JD,Qu J,et al. Study on cell surface receptors of severe fever with thrombocytopenia syndrome virus[J]. Journal of Microbes and Infections,2014,9(2):112-115.
[13]Tani H,Fukuma A,Fukushi S,et al. Efficacy of T-705(favipiravir)in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus[J]. m Sphere,2016,1(1):e00061-15.DOI:10. 1128/m Sphere. 00061-15.
[14]侯志飞,赵学森.干扰素诱导跨膜蛋白抗病毒机制研究进展[J].中华实验和临床感染病杂志:电子版,2018,12(3):212-215. DOI:10. 3877/cma. j. issn. 1674-1358. 2018. 03. 002.Hou ZF,Zhao XS. Advances in antiviral study on interferon-induced transmembrane protein[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Version),2018,12(3):212-215. DOI:10. 3877/cma. j. issn. 1674-1358. 2018. 03. 002.
[15]万佳,张硕,李阿茜,等.干扰素诱导的跨膜蛋白IFITM1/2/3对SFTS病毒感染的影响[J].中华实验和临床病毒学杂志,2016,30(3):279-282. DOI:10. 3760/cma. j. issn. 1003-9279. 2016.03. 006.Wan J,Zhang S,Li AQ,et al. Impact of interferon induced transmembrane proteins IFITM1/2/3 on SFTS virus infection[J].Chinese Journal of Experimental and Clinical Virology,2016,30(3):279-282. DOI:10. 3760/cma. j. issn. 1003-9279. 2016.03. 006.
[16]Li XK,Yang ZD,Du J,et al. Endothelial activation and dysfunction in severe fever with thrombocytopenia syndrome[J]. PLo S Negl Trop Dis,2017,11(8):e0005746. DOI:10. 1371/journal. pntd. 0005746.
[17]Liu Y,Wu B,Paessler S,et al. The pathogenesis of severe fever with thrombocytopenia syndrome virus infection in alpha/beta interferon knockout mice:insights into the pathologic mechanisms of a new viral hemorrhagic fever[J]. J Virol,2014,88(3):1781-1786. DOI:10. 1128/JVI. 02277-13.
[18]Jin C,Liang M,Ning J,et al. Pathogenesis of emerging severe fever with thrombocytopenia syndrome virus in C57/BL6 mouse model[J]. Proc Natl Acad Sci U S A,2012,109(25):10053-10058. DOI:10. 1073/pnas. 1120246109.
[19]Hiraki T,Yoshimitsu M,Suzuki T,et al. Two autopsy cases of severe fever with thrombocytopenia syndrome(SFTS)in Japan:a pathognomonic histological feature and unique complication of SFTS[J]. Pathol Int,2014,64(11):569-575. DOI:10. 1111/pin. 12207.
[20]Kaneko M,Shikata H,Matsukage S,et al. A patient with severe fever with thrombocytopenia syndrome and hemophagocytic lymphohistiocytosis-associated involvement of the central nervous system[J].J Infect Chemother,2018,24(4):292-297. DOI:10. 1016/j. jiac. 2017. 10. 016.
[21]Nakano A, Ogawa H, Nakanishi Y, et al. Hemophagocytic lymphohistiocytosis in a fatal case of severe fever with thrombocytopenia syndrome[J]. Intern Med,2017,56(12):1597-1602.DOI:10. 2169/internalmedicine. 56. 6904.
[22]方汉波,李世波,庄晓玲,等.发热伴血小板减少综合征28例骨髓象特征分析[J].中华临床感染病杂志,2016,9(3):260-264.DOI:10. 3760/cma. j. issn. 1674-2397. 2016. 03. 010.Fang HB,Li SB,Zhuang XL,et al. Morphological characteristics of bone marrow in severe fever with thrombocytopenia syndrome:analysis of 28 cases[J]. Chinese Journal of Clinical Infectious Diseases,2016,9(3):260-264. DOI:10. 3760/cma. j. issn.1674-2397. 2016. 03. 010.
[23]Guo CT,Lu QB,Ding SJ,et al. Epidemiological and clinical characteristics of severe fever with thrombocytopenia syndrome(SFTS)in China:an integrated data analysis[J]. Epidemiol Infect,2016,144(6):1345-1354. DOI:10. 1017/S0950268815002678.
[24]Liu MM,Lei XY,Yu XJ. Meta-analysis of the clinical and laboratory parameters of SFTS patients in China[J]. Virol J,2016,13(1):198.DOI:10. 1186/s12985-016-0661-9.
[25]林果为,王吉耀,葛均波.实用内科学[M]. 15版.北京:人民卫生出版社,2017:357.Lin GW,Wang JY,Ge JB. Practical internal medicine[M]. 15th ed.Beijing:People's Health Publishing House,2017:357.
[26]Gai ZT,Zhang Y,Liang MF,et al. Clinical progress and risk factors for death in severe fever with thrombocytopenia syndrome patients[J]. J Infect Dis,2012,206(7):1095-1102. DOI:10.1093/infdis/jis472.
[27]袁义美,崔宁,袁春.发热伴血小板减少综合征命名、临床分期及分型的建议[J].中华传染病杂志,2016,34(1):57-58. DOI:10. 3760/cma. j. issn. 1000-6680. 2016. 01. 016.Yuan YM,Cui N,Yuan C. Nomenclature,clinical stage and classification of fever with thrombocytopenia syndrome[J]. Chinese Journal of Infectious Diseases,2016,34(1):57-58. DOI:10.3760/cma. j. issn. 1000-6680. 2016. 01. 016.
[28]Li H,Lu QB,Xing B,et al. Epidemiological and clinical features of laboratory-diagnosed severe fever with thrombocytopenia syndrome in China,2011-17:a prospective observational study[J]. Lancet Infect Dis,2018,18(10):1127-1137. DOI:10. 1016/S1473-3099(18)30293-7.
[29]Liu W,Lu Q,Cui N,et al. Case-fatality ratio and effectiveness of ribavirin therapy among hospitalized patients in china who had severe fever with thrombocytopenia syndrome[J]. Clin Infect Dis,2013,57(9):1292-1299. DOI:10. 1093/cid/cit530.
[30]Lu QB,Cui N,Hu JG,et al. Characterization of immunological responses in patients with severe fever with thrombocytopenia syndrome:a cohort study in China[J]. Vaccine,2015,33(10):1250-1255. DOI:10. 1016/j. vaccine. 2015. 01. 051.
[31]Shin J,Kwon D,Youn SK,et al. Characteristics and factors associated with death among patients hospitalized for severe fever with thrombocytopenia syndrome,South Korea,2013[J]. Emerg Infect Dis,2015,21(10):1704-1710. DOI:10. 3201/eid2110.141928.
[32]Takahashi T,Maeda K,Suzuki T,et al. The first identification and retrospective study of Severe Fever with Thrombocytopenia Syndrome in Japan[J]. J Infect Dis,2014,209(6):816-827.DOI:10. 1093/infdis/jit603.
[33]Kato H,Yamagishi T,Shimada T,et al. Epidemiological and clinical features of severe fever with thrombocytopenia syndrome in Japan,2013-2014[J]. PLo S One,2016,11(10):e0165207.DOI:10. 1371/journal. pone. 0165207.
[34]Oh WS,Yoo JR,Kwon KT,et al. Effect of early plasma exchange on survival in patients with severe fever with thrombocytopenia syndrome:a multicenter study[J]. Yonsei Med J,2017,58(4):867-871. DOI:10. 3349/ymj. 2017. 58. 4. 867.
[35]范雪娟,潘琳琳,袁兰,等.静注人免疫球蛋白联合血必净注射液治疗发热伴血小板减少综合征中的治疗价值分析[J].国际医药卫生导报,2016,22(10):1363-1365. DOI:10. 3760/cma.j. issn. 1007-1245. 2016. 10. 007.Fan XJ,Pan LL,Yuan L,et al. Intravenous injection of human immunoglobulin combined with Xuebijing injection in treatment of fever complicated with thrombocytopenia syndrome[J]. International Medicine and Health Guidance News,2016,22(10):1363-1365. DOI:10. 3760/cma. j. issn. 1007-1245. 2016. 10. 007.
[36]Nakamura S,Azuma M,Maruhashi T,et al. Steroid pulse therapy in patients with encephalopathy associated with severe fever with thrombocytopenia syndrome[J]. J Infect Chemother,2018,24(5):389-392. DOI:10. 1016/j. jiac. 2017. 11. 004.
[37]Graci JD,Cameron CE. Mechanisms of action of ribavirin against distinct viruses[J]. Rev Med Virol,2006,16(1):37-48. DOI:10. 1002/rmv. 483.
[38]邓宝成,王进勇,毛雪兰,等.利巴韦林治疗发热伴血小板减少综合征的疗效观察[J].实用药物与临床,2017,20(11):1297-1300. DOI:10. 14053/j. cnki. ppcr. 201711018.Deng BC,Wang JY,Mao XL,et al. Efficacy of ribavirin in the treatment of severe fever with thrombocytopenia syndrome[J].Practical Pharmacy and Clinical Remedies,2017,20(11):1297-1300. DOI:10. 14053/j. cnki. ppcr. 201711018.
[39]陶林辉,管敏昌,彭苍骄,等.小儿氨酚黄那敏颗粒联合利巴韦林气雾剂治疗急性上呼吸道感染疗效观察[J].中国医药,2015,10(2):177-179. DOI:10. 3760/cma. j. issn. 1673-4777.2015. 02. 009.Tao LH,Guan MC,Peng CJ,et al. The therapeutic efficacy of pediatric paracetamol combined with ribavirin aerosol in children with acute upper respiratory tract infection[J]. China Medicine,2015,10(2):177-179. DOI:10. 3760/cma. j. issn. 1673-4777.2015. 02. 009.
[40]Shimojima M,Fukushi S,Tani H,et al. Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection[J]. Virol J,2015(12):181. DOI:10.1186/s12985-015-0412-3.
[41]Lu QB,Zhang SY,Cui N,et al. Common adverse events associated with ribavirin therapy for Severe Fever with Thrombocytopenia Syndrome[J]. Antiviral Res,2015(119):19-22. DOI:10. 1016/j.antiviral. 2015. 04. 006.
[42]Scharton D,Bailey KW,Vest Z,et al. Favipiravir(T-705)protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment[J].Antiviral Res,2014(104):84-92. DOI:10. 1016/j. antiviral. 2014.01. 016.
[43]Gowen BB,Westover JB,Miao J,et al. Modeling severe fever with thrombocytopenia syndrome virus infection in golden syrian hamsters:importance of STAT2 in preventing disease and effective treatment with favipiravir[J]. J Virol,2017,91(3):e01942-16.DOI:10. 1128/JVI. 01942-16.
[2]唐霜,沈姝,史君明,等.布尼亚病毒目新分类概述[J].生物多样性,2018,26(9):1004-1015. DOI:10. 17520/biods. 2018042.Tang S,Shen S,Shi JM,et al. A review and novel classification of Bunyavirales[J]. Biodiversity Science,2018,26(9):1004-1015. DOI:10. 17520/biods. 2018042.
[3]Kim WY,Choi W,Park SW,et al. Nosocomial transmission of severe fever with thrombocytopenia syndrome in Korea[J]. Clin Infect Dis,2015,60(11):1681-1683. DOI:10. 1093/cid/civ128.
[4]Jianbo ZQWJ. Current status of severe fever with thrombocytopenia syndrome in China[J]. Virol Sin,2017,32(1):51-62. DOI:10.1007/s12250-016-3931-1.
[5]Wang M,Zuo J,Hu K. Identification of severe fever with thrombocytopenia syndrome virus in ticks collected from patients[J]. Int J Infect Dis,2014(29):82-83. DOI:10. 1016/j. ijid. 2014.09. 008.
[6]Yu XJ,Liang MF,Zhang SY,et al. Fever with thrombocytopenia associated with a novel bunyavirus in China[J]. N Engl J Med,2011,364(16):1523-1532. DOI:10. 1056/NEJMoa1010095.
[7]Wu Y,Zhu Y,Gao F,et al. Structures of phlebovirus glycoprotein Gn and identification of a neutralizing antibody epitope[J]. Proc Natl Acad Sci U S A,2017,114(36):E7564-7573. DOI:10. 1073/pnas. 1705176114.
[8]Sun Y,Qi Y,Liu C,et al. Nonmuscle myosin heavy chainⅡA is a critical factor contributing to the efficiency of early infection of severe fever with thrombocytopenia syndrome virus[J]. J Virol,2014,88(1):237-248. DOI:10. 1128/JVI. 02141-13.
[9]Plegge T,Hofmann-Winkler H,Spiegel M,et al. Evidence that processing of the severe fever with thrombocytopenia syndrome virus Gn/Gc polyprotein is critical for viral infectivity and requires an internal Gc signal peptide[J]. Plo S One, 2016,11(11):e166013. DOI:10. 1371/journal. pone. 0166013.
[10]Hofmann H,Li X,Zhang X,et al. Severe fever with thrombocytopenia virus glycoproteins are targeted by neutralizing antibodies and can use DC-SIGN as a receptor for p H-dependent entry into human and animal cell lines[J]. J Virol,2013,87(8):4384-4394. DOI:10. 1128/JVI. 02628-12.
[11]何程程,李阿茜,刘林,等.发热伴血小板减少综合征布尼亚病毒细胞嗜性研究[J].中华实验和临床病毒学杂志,2014,28(1):10-13. DOI:10. 3760/cma. j. issn. 1003-9279. 2014. 01. 004.He CC,Li AQ,Liu L,et al. The susceptibility of culture cells to severe fever with thrombocytopenia syndrome virus[J]. Chinese Journal of Experimental and Clinical Virology,2014,28(1):10-13. DOI:10. 3760/cma. j. issn. 1003-9279. 2014. 01. 004.
[12]张硕,李建东,曲靖,等.发热伴血小板减少综合征病毒细胞表面受体的初步研究[J].微生物与感染,2014,9(2):112-115.Zhang S,Li JD,Qu J,et al. Study on cell surface receptors of severe fever with thrombocytopenia syndrome virus[J]. Journal of Microbes and Infections,2014,9(2):112-115.
[13]Tani H,Fukuma A,Fukushi S,et al. Efficacy of T-705(favipiravir)in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus[J]. m Sphere,2016,1(1):e00061-15.DOI:10. 1128/m Sphere. 00061-15.
[14]侯志飞,赵学森.干扰素诱导跨膜蛋白抗病毒机制研究进展[J].中华实验和临床感染病杂志:电子版,2018,12(3):212-215. DOI:10. 3877/cma. j. issn. 1674-1358. 2018. 03. 002.Hou ZF,Zhao XS. Advances in antiviral study on interferon-induced transmembrane protein[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Version),2018,12(3):212-215. DOI:10. 3877/cma. j. issn. 1674-1358. 2018. 03. 002.
[15]万佳,张硕,李阿茜,等.干扰素诱导的跨膜蛋白IFITM1/2/3对SFTS病毒感染的影响[J].中华实验和临床病毒学杂志,2016,30(3):279-282. DOI:10. 3760/cma. j. issn. 1003-9279. 2016.03. 006.Wan J,Zhang S,Li AQ,et al. Impact of interferon induced transmembrane proteins IFITM1/2/3 on SFTS virus infection[J].Chinese Journal of Experimental and Clinical Virology,2016,30(3):279-282. DOI:10. 3760/cma. j. issn. 1003-9279. 2016.03. 006.
[16]Li XK,Yang ZD,Du J,et al. Endothelial activation and dysfunction in severe fever with thrombocytopenia syndrome[J]. PLo S Negl Trop Dis,2017,11(8):e0005746. DOI:10. 1371/journal. pntd. 0005746.
[17]Liu Y,Wu B,Paessler S,et al. The pathogenesis of severe fever with thrombocytopenia syndrome virus infection in alpha/beta interferon knockout mice:insights into the pathologic mechanisms of a new viral hemorrhagic fever[J]. J Virol,2014,88(3):1781-1786. DOI:10. 1128/JVI. 02277-13.
[18]Jin C,Liang M,Ning J,et al. Pathogenesis of emerging severe fever with thrombocytopenia syndrome virus in C57/BL6 mouse model[J]. Proc Natl Acad Sci U S A,2012,109(25):10053-10058. DOI:10. 1073/pnas. 1120246109.
[19]Hiraki T,Yoshimitsu M,Suzuki T,et al. Two autopsy cases of severe fever with thrombocytopenia syndrome(SFTS)in Japan:a pathognomonic histological feature and unique complication of SFTS[J]. Pathol Int,2014,64(11):569-575. DOI:10. 1111/pin. 12207.
[20]Kaneko M,Shikata H,Matsukage S,et al. A patient with severe fever with thrombocytopenia syndrome and hemophagocytic lymphohistiocytosis-associated involvement of the central nervous system[J].J Infect Chemother,2018,24(4):292-297. DOI:10. 1016/j. jiac. 2017. 10. 016.
[21]Nakano A, Ogawa H, Nakanishi Y, et al. Hemophagocytic lymphohistiocytosis in a fatal case of severe fever with thrombocytopenia syndrome[J]. Intern Med,2017,56(12):1597-1602.DOI:10. 2169/internalmedicine. 56. 6904.
[22]方汉波,李世波,庄晓玲,等.发热伴血小板减少综合征28例骨髓象特征分析[J].中华临床感染病杂志,2016,9(3):260-264.DOI:10. 3760/cma. j. issn. 1674-2397. 2016. 03. 010.Fang HB,Li SB,Zhuang XL,et al. Morphological characteristics of bone marrow in severe fever with thrombocytopenia syndrome:analysis of 28 cases[J]. Chinese Journal of Clinical Infectious Diseases,2016,9(3):260-264. DOI:10. 3760/cma. j. issn.1674-2397. 2016. 03. 010.
[23]Guo CT,Lu QB,Ding SJ,et al. Epidemiological and clinical characteristics of severe fever with thrombocytopenia syndrome(SFTS)in China:an integrated data analysis[J]. Epidemiol Infect,2016,144(6):1345-1354. DOI:10. 1017/S0950268815002678.
[24]Liu MM,Lei XY,Yu XJ. Meta-analysis of the clinical and laboratory parameters of SFTS patients in China[J]. Virol J,2016,13(1):198.DOI:10. 1186/s12985-016-0661-9.
[25]林果为,王吉耀,葛均波.实用内科学[M]. 15版.北京:人民卫生出版社,2017:357.Lin GW,Wang JY,Ge JB. Practical internal medicine[M]. 15th ed.Beijing:People's Health Publishing House,2017:357.
[26]Gai ZT,Zhang Y,Liang MF,et al. Clinical progress and risk factors for death in severe fever with thrombocytopenia syndrome patients[J]. J Infect Dis,2012,206(7):1095-1102. DOI:10.1093/infdis/jis472.
[27]袁义美,崔宁,袁春.发热伴血小板减少综合征命名、临床分期及分型的建议[J].中华传染病杂志,2016,34(1):57-58. DOI:10. 3760/cma. j. issn. 1000-6680. 2016. 01. 016.Yuan YM,Cui N,Yuan C. Nomenclature,clinical stage and classification of fever with thrombocytopenia syndrome[J]. Chinese Journal of Infectious Diseases,2016,34(1):57-58. DOI:10.3760/cma. j. issn. 1000-6680. 2016. 01. 016.
[28]Li H,Lu QB,Xing B,et al. Epidemiological and clinical features of laboratory-diagnosed severe fever with thrombocytopenia syndrome in China,2011-17:a prospective observational study[J]. Lancet Infect Dis,2018,18(10):1127-1137. DOI:10. 1016/S1473-3099(18)30293-7.
[29]Liu W,Lu Q,Cui N,et al. Case-fatality ratio and effectiveness of ribavirin therapy among hospitalized patients in china who had severe fever with thrombocytopenia syndrome[J]. Clin Infect Dis,2013,57(9):1292-1299. DOI:10. 1093/cid/cit530.
[30]Lu QB,Cui N,Hu JG,et al. Characterization of immunological responses in patients with severe fever with thrombocytopenia syndrome:a cohort study in China[J]. Vaccine,2015,33(10):1250-1255. DOI:10. 1016/j. vaccine. 2015. 01. 051.
[31]Shin J,Kwon D,Youn SK,et al. Characteristics and factors associated with death among patients hospitalized for severe fever with thrombocytopenia syndrome,South Korea,2013[J]. Emerg Infect Dis,2015,21(10):1704-1710. DOI:10. 3201/eid2110.141928.
[32]Takahashi T,Maeda K,Suzuki T,et al. The first identification and retrospective study of Severe Fever with Thrombocytopenia Syndrome in Japan[J]. J Infect Dis,2014,209(6):816-827.DOI:10. 1093/infdis/jit603.
[33]Kato H,Yamagishi T,Shimada T,et al. Epidemiological and clinical features of severe fever with thrombocytopenia syndrome in Japan,2013-2014[J]. PLo S One,2016,11(10):e0165207.DOI:10. 1371/journal. pone. 0165207.
[34]Oh WS,Yoo JR,Kwon KT,et al. Effect of early plasma exchange on survival in patients with severe fever with thrombocytopenia syndrome:a multicenter study[J]. Yonsei Med J,2017,58(4):867-871. DOI:10. 3349/ymj. 2017. 58. 4. 867.
[35]范雪娟,潘琳琳,袁兰,等.静注人免疫球蛋白联合血必净注射液治疗发热伴血小板减少综合征中的治疗价值分析[J].国际医药卫生导报,2016,22(10):1363-1365. DOI:10. 3760/cma.j. issn. 1007-1245. 2016. 10. 007.Fan XJ,Pan LL,Yuan L,et al. Intravenous injection of human immunoglobulin combined with Xuebijing injection in treatment of fever complicated with thrombocytopenia syndrome[J]. International Medicine and Health Guidance News,2016,22(10):1363-1365. DOI:10. 3760/cma. j. issn. 1007-1245. 2016. 10. 007.
[36]Nakamura S,Azuma M,Maruhashi T,et al. Steroid pulse therapy in patients with encephalopathy associated with severe fever with thrombocytopenia syndrome[J]. J Infect Chemother,2018,24(5):389-392. DOI:10. 1016/j. jiac. 2017. 11. 004.
[37]Graci JD,Cameron CE. Mechanisms of action of ribavirin against distinct viruses[J]. Rev Med Virol,2006,16(1):37-48. DOI:10. 1002/rmv. 483.
[38]邓宝成,王进勇,毛雪兰,等.利巴韦林治疗发热伴血小板减少综合征的疗效观察[J].实用药物与临床,2017,20(11):1297-1300. DOI:10. 14053/j. cnki. ppcr. 201711018.Deng BC,Wang JY,Mao XL,et al. Efficacy of ribavirin in the treatment of severe fever with thrombocytopenia syndrome[J].Practical Pharmacy and Clinical Remedies,2017,20(11):1297-1300. DOI:10. 14053/j. cnki. ppcr. 201711018.
[39]陶林辉,管敏昌,彭苍骄,等.小儿氨酚黄那敏颗粒联合利巴韦林气雾剂治疗急性上呼吸道感染疗效观察[J].中国医药,2015,10(2):177-179. DOI:10. 3760/cma. j. issn. 1673-4777.2015. 02. 009.Tao LH,Guan MC,Peng CJ,et al. The therapeutic efficacy of pediatric paracetamol combined with ribavirin aerosol in children with acute upper respiratory tract infection[J]. China Medicine,2015,10(2):177-179. DOI:10. 3760/cma. j. issn. 1673-4777.2015. 02. 009.
[40]Shimojima M,Fukushi S,Tani H,et al. Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection[J]. Virol J,2015(12):181. DOI:10.1186/s12985-015-0412-3.
[41]Lu QB,Zhang SY,Cui N,et al. Common adverse events associated with ribavirin therapy for Severe Fever with Thrombocytopenia Syndrome[J]. Antiviral Res,2015(119):19-22. DOI:10. 1016/j.antiviral. 2015. 04. 006.
[42]Scharton D,Bailey KW,Vest Z,et al. Favipiravir(T-705)protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment[J].Antiviral Res,2014(104):84-92. DOI:10. 1016/j. antiviral. 2014.01. 016.
[43]Gowen BB,Westover JB,Miao J,et al. Modeling severe fever with thrombocytopenia syndrome virus infection in golden syrian hamsters:importance of STAT2 in preventing disease and effective treatment with favipiravir[J]. J Virol,2017,91(3):e01942-16.DOI:10. 1128/JVI. 01942-16.